Clicky

Oryzon Genomics SA(ORY)

Description: Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.


Keywords: Cancer Cns Disorders Kdm1a

Home Page: www.oryzon.com

Sant Ferran 74
Cornellà de Llobregat, 08940
Spain
Phone: 34 93 515 13 13


Officers

Name Title
Dr. Carlos Manuel Buesa Arjol Co-Founder, Chairman, CEO & Pres
Mr. Enric Rello Condomines Director of Operations, COO & CFO
Mr. Jordi Xaus Pey Chief Scientific Officer
Mr. Xavier Perpinya Ribera Head of Internal Audit & Compliance
Mr. Emili Torrell Cortada Chief Bus. Devel. Officer
Ms. Neus Virgili Bernado Chief Intellectual Property Officer
Dr. Michael Thomas Ropacki Ph.D. Chief Medical Officer of CNS
Ms. Sonia Paloma Gutierrez Bezon Chief of Clinical Operations
Dr. Saikat Nandi Global Chief Bus. Officer
Dr. Ana Limon Sr. VP of Clinical Devel. & Global Medical Affairs

Exchange: MC

Country: ES

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.6455
Price-to-Sales TTM: 12.1667
IPO Date:
Fiscal Year End: December
Full Time Employees: 43
Back to stocks